Minerva Neurosciences, Inc. — Q2 2017 Form 10-Q
Reporting period: Quarter and six months ended June 30, 2017. Minerva is a clinical-stage biopharmaceutical company developing CNS therapies; it had no approved products and generated no product revenue.
Financial results and liquidity
| Metric | Q2 2017 / June 30, 2017 | Comparable period / December 31, 2016 |
|---|---|---|
| Revenue | No product revenue | No product revenue |
| Research and development expense | $7.1 million for the quarter; $14.8 million for six months | $2.7 million for Q2 2016; $8.1 million for six months |
| General and administrative expense | $2.6 million for the quarter; $5.5 million for six months | $2.3 million for Q2 2016; $4.6 million for six months |
| Net loss | $9.8 million for the quarter; $20.4 million for six months; six-month loss per share $0.57 | $5.2 million for Q2 2016; $13.2 million for six months; six-month loss per share $0.47 |
| Cash, cash equivalents and marketable securities | $77.6 million, including $50.2 million cash and $27.4 million marketable securities | $83.0 million cash and cash equivalents at December 31, 2016 |
| Operating cash flow | $(12.9) million for six months | $(12.1) million for six months of 2016 |
| Debt | $6.0 million Term A principal outstanding; matures August 2018 | $8.7 million principal at December 31, 2016 |
Gross margin is not applicable because the company had no product sales. Total assets were $127.4 million and total liabilities were $29.3 million at June 30, 2017. Current assets were $78.1 million versus current liabilities of $14.6 million. The company reported a $153.3 million accumulated deficit.
Changes versus the prior comparable period
- Q2 net loss widened to $9.8 million from $5.2 million; six-month net loss widened to $20.4 million from $13.2 million.
- Six-month R&D expense rose $6.7 million, primarily reflecting MIN-202 Phase II preparation, increased MIN-101 spending and higher stock compensation; completion of the MIN-117 Phase IIa trial partly offset the increase.
- Six-month operating cash use increased by about $0.8 million. Financing provided $7.5 million, mainly from warrant and option exercises, partly offset by $2.4 million of loan repayments. Investing used $27.4 million, principally to purchase marketable securities.
- Cash and cash equivalents declined from $83.0 million at year-end, while the company held $27.4 million of short-term marketable securities at June 30.
Outlook, management commentary and risks
- Management expected existing cash, cash equivalents and marketable securities to fund commitments for at least 12 months after the interim statements were issued, while stating additional capital would be needed for continued operations and later-stage development. The company expected continuing losses and negative operating cash flow.
- On July 5, 2017, after quarter-end, Minerva completed a public offering of 5.75 million shares at $7.75 per share, for approximately $41.5 million in net proceeds. Shares outstanding were 42,509,003 as of July 31, 2017.
- A June 2017 Janssen amendment was not effective at June 30 and remained subject to European Commission review and other conditions. If effective, Janssen would provide $30 million upfront, plus $20 million at Phase III trial start and $20 million when half of patients are enrolled, and waive approximately $13 million of remaining Phase II costs. Minerva would assume strategic control and all Phase III insomnia development costs. The amendment could terminate if not effective by August 31, 2017; if it failed, the existing agreement would remain in force.
- Management planned to initiate a pivotal MIN-101 Phase III trial in the second half of 2017: a 12-week, placebo-controlled study of two doses, expected to enroll approximately 500 patients. A new gastric-resistant formulation showed comparable exposure and no QTc prolongation in the bridging trial; the FDA had declined Breakthrough Therapy designation pending additional analyses.
- Key risks include clinical efficacy and safety uncertainty, regulatory and trial delays, reliance on third parties for trials and manufacturing, the need for future financing and potential dilution. MIN-101 QTc concerns and the conditional Janssen amendment are notable near-term uncertainties. The Oxford/SVB loan is secured by substantially all assets other than intellectual property; the company reported compliance with loan covenants.
- No material litigation was identified, and management concluded disclosure controls were effective at a reasonable assurance level.
Important facts for investors to verify
- Whether the Janssen amendment and related share repurchase received the required approvals and became effective by the stated deadline, and whether milestone payments and cost waivers were realized.
- Whether the MIN-101 Phase III trial began on schedule, its final design and enrollment progress, and any further FDA feedback on Breakthrough Therapy designation or QTc analyses.
- Actual cash burn and remaining runway after the July offering, together with the timing and full costs of planned MIN-101 and MIN-202 trials.
- Debt repayment obligations through the August 2018 maturity and any effects of the secured loan covenants on financing or operations.